Vitrification of heart valve tissues.
Vitrification of heart valve tissues.
复制标题
心脏瓣膜组织的玻璃化。
DOI：
10.1007/978-1-4939-2193-5_20
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Campbell LH
中科院分区：
文献类型：
--
作者：
Brockbank KG;Chen Z;Greene ED;Campbell LH
最初用于部分心脏瓣膜的玻璃化冷冻方案在完整的心脏瓣膜上的应用随着时间的推移而演变。使用VS55的议定书1的无冰冷冻保存仅限于有可能以相对快速的冷却和升温速率进行的小样本。与新鲜的未经处理的组织相比，VS55冷冻保存通常可提供约80%的细胞存活率和组织功能。相比之下，使用VS83的无冰冷冻保存方案2和3比传统的冷冻保存方法和VS55保存有几个优势，包括在−80℃下长期保存的能力；在保持材料特性的同时比冷冻保存更好的基质；非常低的细胞存活率，降低了体内发生免疫反应的风险；降低了与使用液氮相关的微生物污染风险；改进了体内功能；没有明显的受体同种异体免疫反应；简化了制造过程；由于不使用液氮，提高了操作员的安全性；以及降低了制造成本。
Application of the original vitrification protocol used for pieces of heart valves to intact heart valves has evolved over time. Ice-free cryopreservation by Protocol 1 using VS55 is limited to small samples where relatively rapid cooling and warming rates are possible. VS55 cryopreservation typically provides extracellular matrix preservation with approximately 80 % cell viability and tissue function compared with fresh untreated tissues. In contrast, ice-free cryopreservation using VS83, Protocols 2 and 3, has several advantages over conventional cryopreservation methods and VS55 preservation, including long-term preservation capability at −80 °C; better matrix preservation than freezing with retention of material properties; very low cell viability, reducing the risks of an immune reaction in vivo; reduced risks of microbial contamination associated with use of liquid nitrogen; improved in vivo functions; no significant recipient allogeneic immune response; simplified manufacturing process; increased operator safety because liquid nitrogen is not used; and reduced manufacturing costs.